Order results by:
| Issue | Title | |
| Vol 15, No 1 (2022) | Study of methods for state regulation of prices and costs of the health care system for medicines in the United Kingdom | Abstract similar documents |
| A. A. Leshkevich, D. S. Yurochkin, Z. M. Golant, I. A. Narkevich | ||
| "... Objective: analysis of state regulation of prices and costs for the purchase of medicines (drugs ..." | ||
| Vol 10, No 4 (2017) | IMPROVEMENT OF PRICE REGULATION FOR INNOVATIVE MEDICINES COVERED BY THE NATIONAL BUDGET | Abstract similar documents |
| V. A. Lemeshko, N. Z. Musina, V. K. Fedyaeva | ||
| "... the therapeutic value of the drug into its consumer price. The drug pricing system existing in the Russian ..." | ||
| Vol 13, No 2 (2020) | Review of calculation methods, procedures for registration and re-registration of producer prices of medicines in the countries of the Eurasian Economic Union | Abstract similar documents |
| A. A. Leshkevich, D. S. Yurochkin, Z. M. Golant, I. A. Narkevich | ||
| "... Aim. To analyze the methods of the state regulation of prices for the manufacturers ..." | ||
| Vol 7, No 4 (2014) | ROAD MAP FOR DEVELOPMENT OF PRICE REGULATION SYSTEM AND SYSTEM OF DRUG SUPPLY AT THE EXPENSE OF RUSSIAN FEDERATION HEALTHCARE SYSTEM FUNDS | Abstract similar documents |
| M. V. Sura, K. V. Gerasimova, V. V. Omelyanovskiy, M. V. Avksentieva | ||
| "... study goal is to prepare a road map for development of price regulation system and system of drug ..." | ||
| Vol 10, No 4 (2017) | INTERNATIONAL APPROACHES TO THE GOVERNMENT PRICE CONTROL OVER GENERICS AND BIOSIMILARS: A REVIEW | Abstract similar documents |
| D. G. Tolkacheva, A. V. Torgov, A. S. Margazova | ||
| "... Objective. In this review, we analyzed the policies for price controls on generics and biosimilars ..." | ||
| Vol 10, No 4 (2017) | INTERNATIONAL APPROACHES TO THE GOVERNMENT PRICE CONTROL OVER GENERICS AND BIOSIMILARS: A REVIEW | Abstract similar documents |
| D. G. Tolkacheva, A. V. Torgov, A. S. Margazova | ||
| "... Objective. In this review, we analyzed the policies for price controls on generics and biosimilars ..." | ||
| Vol 12, No 2 (2019) | Dynamics of prices and consumption of anticancer drugs in Russia after their generics and biosimilars became available | Abstract similar documents |
| F. V. Gorkavenko, A. V. Nikitina, E. S. Saibel’, M. V. Avksent’eva, M. V. Sura, D. V. Fedyaev | ||
| "... trends in the general picture of drug prices and consumption. In the present study, we analyze ..." | ||
| Vol 16, No 4 (2023) | Peculiarities of real-world data application for health technology assessment in Asian countries | Abstract similar documents |
| B. B. Kondratyeva, F. V. Gorkavenko, V. V. Omelyanovskiy | ||
| "... of this direction, adopted regulations, developed methodological guidelines, promising areas of application ..." | ||
| Vol 8, No 3 (2015) | LEGAL REGULATION OF STATE MANAGEMENT OF MEDICAL SCIENCE | Abstract similar documents |
| L. S. Melnikova, O. Yu. Rebrova, V. V. Omelyanovskiy | ||
| "... The article presents an analysis of the general legal regulation of medical research ..." | ||
| Vol 10, No 2 (2017) | THE USE OF MULTI-CRITERIAL DECISION ANALYSIS (MCDA) FOR ESTIMATING THE THERAPEUTIC VALUE OF INNOVATIVE DRUGS | Abstract similar documents |
| V. K. Fedyaeva, V. V. Omelyanovskiy, N. Z. Musina, G. R. Khachatryan, O. I. Ivakhnenko | ||
| "... as a major criterion in negotiations on medicine prices. The existing tools for assessing the therapeutic ..." | ||
| Vol 17, No 3 (2024) | Biologically active supplements overview: regulation, market trends, application, and health impact | Abstract similar documents |
| A. M. Stepanova, A. N. Plutnitskiy, E. V. Gameeva | ||
| "... . The object of this review was to summarize the available foreign data on the regulation of using BAS ..." | ||
| Vol 17, No 1 (2024) | Compounding pharmacy regulations: experience of the Latvian pharmaceutical market | Abstract similar documents |
| D. D. Mamedov, D. S. Yurochkin, D. D. Zelikova, S. E. Erdni-Garyaev, Z. M. Golant, I. A. Narkevich | ||
| "... pharmaceutical market to improve approaches for statutory regulation of this special and socially significant ..." | ||
| Vol 10, No 1 (2017) | RESTRICTIVE LISTS OF DRUGS: REGULATIONS, FUNCTIONS, SOURCES OF FINANCE, AND GUIDELINES FOR CREATION | Abstract similar documents |
| M. V. Sura | ||
| "... The present report reviews various aspects of legal regulation, function, guidelines for creation ..." | ||
| Vol 16, No 1 (2023) | Compounding pharmacy regulations: experience of the North American pharmaceutical market | Abstract similar documents |
| D. D. Mamedov, D. S. Yurochkin, A. A. Leshkevich, S. E. Erdni-Garyaev, Z. M. Golant, I. A. Narkevich | ||
| "... In order to improve regulation of socially significant type of activity in the field ..." | ||
| Vol 14, No 2 (2021) | Pharmacoeconomic aspects of oral vinorelbine application: a budget impact analysis considering the new registered price | Abstract similar documents |
| D. A. Ivanov, I. N. Dyakov, S. K. Zyryanov | ||
| "... as indicated, taking into consideration the new registered price. Material and methods. A clinical-economic ..." | ||
| Vol 14, No 4 (2021) | Development of the system of state financing of Compulsory Health Insurance | Abstract similar documents |
| А. V. Larionov, S. V. Russkikh, S. V. Maslennikov | ||
| Vol 7, No 3 (2014) | ASSESSMENT OF NECESSARY FINANCIAL EXPENSES ON THE DRUG SUPPLY OF THE PATIENTS WITH ORPHAN DISEASES IN THE RUSSIAN FEDERATION | Abstract similar documents |
| M. V. Sura, K. V. Gerasimova, V. V. Omelyanovskiy, M. V. Avksentyeva | ||
| "... of orphan drugs and to carry out state regulation of prices, to ensure increase of regional funding ..." | ||
| Vol 8, No 3 (2015) | COMPARATIVE PHARMACOECONOMIC STUDY OF VITAMIN-MINERAL COMPLEXES FOR REHABILITATION DURING THE PERIOD OF INCREASED NEEDS FOR MICRONUTRIENTS | Abstract similar documents |
| A. Yu. Belinskaya, I. Yu. Torshin, T. R. Grishina, O. A. Gromova | ||
| "... CMC both in quality and price. Results: Based on the assessment of pharmacological quality and price ..." | ||
| Vol 7, No 4 (2014) | ANALYSIS OF GOVERNMENT PROCUREMENTS OF MEDICINES APPLIED IN RARE DISEASES THERAPY | Abstract similar documents |
| D. V. Fedyaev, V. K. Fedyaeva, V. V. Omelyanovsky | ||
| "... drugs, the level of price reduction as a result of trading, the amount and volume of purchases ..." | ||
| Vol 13, No 3 (2020) | Regulatory framework of the oncological medical care provision | Abstract similar documents |
| S. N. Tishkina, V. E. Matskevich, Yu. A. Ledovskikh, E. V. Semakova, V. V. Omelyanovskiy | ||
| "... medical care, the authors studied the normative regulation of the issues of both resources’ provision ..." | ||
| Vol 10, No 1 (2017) | BIOLOGICAL THERAPY IN ADULT PATIENTS WITH ULCERATIVE COLITIS AND CROHN’S DISEASE: BUDGET IMPACT ANALYSIS | Abstract similar documents |
| E. A. Pyadushkina | ||
| "... analysis, published reports on inflammatory bowel disease (IBD) treatment, the highest quoted prices ..." | ||
| Vol 17, No 4 (2024) | Regional aspects of availability of expectorants and antitussive drugs | Abstract similar documents |
| V. М. Timiryanova, А. V. Samorodov, Z. А. Valiullina, V. B. Prudnikov, D. Kh. Krasnoselskaya | ||
| "... differentiation in the availability of individual drugs and their price levels, which determines the variability ..." | ||
| Vol 10, No 2 (2017) | COSTS OF ANTIRETROVIRAL DRUGS USED IN THE THERAPY OF HIV-INFECTED PATIENTS: A PHARMACOECONOMIC ANALYSIS | Abstract similar documents |
| M. B. Kubaeva, Y. Sh. Guchshina | ||
| "... -sponsored prices and the retail prices of these medications has an impact on the costs of ant-HIV therapy. ..." | ||
| Vol 8, No 2 (2015) | CLINICAL AND ECONOMIC ANALYSIS OF THE USE OF DIFFERENT TYPES OF SYSTEMS OF VENOUS ACCESS IN THE TREATMENT OF CHILDREN WITH CANCER | Abstract similar documents |
| Maksim Yur'evich Rykov, Vladimir Georgievich Polyakov | ||
| "... . To calculate the cost price were taken «Price list of paid medical services» and Rates of the compulsory health ..." | ||
| Vol 9, No 3 (2016) | CLINICAL AND ECONOMIC EVALUATION OF LACOSAMIDE IN PATIENTS WITH PARTIAL EPILEPSY | Abstract similar documents |
| E. A. Pyadushkina, M. Yu. Frolov | ||
| "... and essential medicines (VEM), price of public purchases of drugs and regulations of financial costs per unit ..." | ||
| Vol 16, No 1 (2023) | Principles of medical care standards development based on clinical guidelines | Abstract similar documents |
| Yu. A. Ledovskikh, S. N. Tishkina, G. I. Pirova, E. V. Semakova, V. V. Omelyanovskiy | ||
| "... issues that require additional regulation, such as the standard form, the methodology of medical ..." | ||
| Vol 9, No 3 (2016) | EARLY HEALTH TECHNOLOGIES ASSESSMENT — NEW APPROACH TO IMPROVING THE EFFICIENCY OF THE MEDICAL TECHNOLOGY DEVELOPMENT PROCESS | Abstract similar documents |
| N. Z. Musina, V. V. Omelyanovskiy, A. V. Krasheninnikova | ||
| "... trials, to predict the probability of formulary inclusion, and to define socially acceptable price. ..." | ||
| Vol 15, No 2 (2022) | The current state of the veterinary drugs market in the Tyumen Region | Abstract similar documents |
| V. V. Byshenko, О. I. Knysh, L. N. Zadirachenko, А. О. Egorova, Yu. S. Rodina | ||
| "... clinics in the Tyumen Region (33); price lists of veterinary pharmaceutical organizations; questionnaires ..." | ||
| Vol 5, No 1 (2012) | UN MILLENNIUM DEVELOPMENT GOALS INDICATORS ON PROBLEMS OF ACCESS TO ESSENTIAL MEDICINES AND ENHANCEMENT OF LOCAL PHARMACEUTICAL PRODUCER IN DEVELOPING COUNTRIES | Abstract similar documents |
| A. Y. Kulikov, A. G. Voskanyan | ||
| Vol 17, No 1 (2024) | Analysis of the availability of bronchodilators and anti-inflammatory drugs for patients with chronic obstructive pulmonary disease | Abstract PDF (Eng) similar documents |
| E. A. Orlova, V. I. Petrov, I. P. Dorfman, O. V. Shatalova, M. A. Orlov | ||
| "... in the Russian Federation. Objective: to assess drug prices, affordability, and availability for COPD patients ..." | ||
| Vol 14, No 2 (2021) | Analysis of the availability and affordability of pharmaceuticals for children in need of palliative care | Abstract similar documents |
| D. M. Medvedeva, I. A. Narkevich, O. D. Nemyatykh | ||
| "... of palliative care. Materials and methods. The price, affordability and physical availability ..." | ||
| Vol 5, No 2 (2012) | WORKING OUT OF STRATEGY OF STOREKEEPING OF PHARMACEUTICAL FIRM | Abstract similar documents |
| A. I. Borodin | ||
| "... . Instability of economy during the periods of crisis, instability of prices on pharmaceutical production ..." | ||
| Vol 14, No 3 (2021) | Review of methods for planning the scope of medical care and financing of the healthcare system by the subjects of the Russian Federation | Abstract similar documents |
| S. A. Kovaleva, D. V. Fedyaev, N. N. Sisigina | ||
| Vol 17, No 4 (2024) | Pharmacoeconomic study of active psoriatic arthritis treatment | Abstract similar documents |
| A. V. Rudakova, Т. V. Korotaeva | ||
| "... retail prices, inclusive of value-added tax. In case of availability of biosimilars/generics ..." | ||
| Vol 9, No 4 (2016) | FACTORS AND EFFECTS OF PRIVATE HEALTH SPENDING | Abstract similar documents |
| O. A. Zarubina, N. N. Sisigina | ||
| "... insurance) and non-discretionary factors (relative health services price, income and its distribution, age ..." | ||
| Vol 10, No 2 (2017) | COST-EFFECTIVENESS OF VILANEROL / UMECLIDINIUM VERSUS TIOTROPIUM IN SEVERE AND VERY SEVERE COPD | Abstract similar documents |
| E. G. Kosolapov, F. S. Kochenkov, N. L. Pogudina, D. V. Blinov | ||
| "... regimens were calculated from the registered data on the maximum selling prices of VED drugs or from ..." | ||
| Vol 8, No 1 (2015) | SOCIAL AND ECONOMIC BURDEN OF FIVE NATURAL FOCAL INFECTIONS IN THE RUSSIAN FEDERATION | Abstract similar documents |
| A. E. Platonov, N. A. Avksentyev, M. V. Avksentyeva, E. V. Derkach, O. V. Platonova, A. V. Titkov, N. M. Kolyasnikova | ||
| "... with vector-borne infectious diseases comprised 909 million rubles in prices of 2011; most of the value ..." | ||
| Vol 11, No 1 (2018) | Options to optimize the access to biosimilars: analysis and solutions | Abstract similar documents |
| O. V. Kirsanova, V. V. Omelyanovsky | ||
| Vol 11, No 4 (2018) | Direct medical costs of using enzalutamide or abiraterone in chemotherapy-naïve patients with metastatic castration resistant prostate cancer | Abstract similar documents |
| N. A. Avxentyev, A. S. Makarov, M. Yu. Frolov | ||
| "... direct medical costs (price of the drugs) of using enzalutamide or abiraterone for treatment ..." | ||
| Vol 11, No 3 (2018) | Pharmacoeconomic analysis of using belimumab for the treatment of systemic lupus erythematosus | Abstract similar documents |
| A. G. Tolkushin, N. L. Pogudina | ||
| "... from analysis of published clinical and observational studies. The prices of the relevant drugs were ..." | ||
| Vol 17, No 1 (2024) | Pharmacoeconomic evaluation of first-line combination therapy with immunotherapy drugs and platinum-containing chemotherapy in adult patients with metastatic non-squamous non-small cell lung cancer | Abstract similar documents |
| S. К. Zyryanov, I. N. Dyakov | ||
| "... on the registered prices according to the state register of maximum selling prices. Results. The use ..." | ||
| Vol 18, No 1 (2025) | Reorganization of public procurement of biosimilars and its economic effect on the monoclonal antibody market in Russia | Abstract similar documents |
| A. Yu. Efremov, A. M. Vlasov, V. I. Gegechkori, N. V. Gorpinchenko, G. V. Ramenskaya, T. M. Litvinova | ||
| "... and marketing methods, including normalization of drug costs to weighted average prices (rub/mg), ABC analysis ..." | ||
| Vol 12, No 2 (2019) | New framework for the development of clinical guidelines in Russia | Abstract similar documents |
| D. V. Blinov, E. S. Akarachkova, A. S. Orlova, E. V. Kryukov, D. I. Korabelnikov | ||
| "... Aim - based on the existing regulations and recent documents from the regulatory bodies, determine ..." | ||
| Vol 8, No 4 (2015) | CLINICAL AND ECONOMIC EVALUATION OF THROMBOPOIETIN RECEPTOR AGONISTS IN THE TREATMENT OF CHRONIC IDIOPATHIC THROMBOCYTOPENIC PURPURA IN ADULTS | Abstract similar documents |
| E. A. Pyadushkina, M. Yu. Frolov, M. V. Avksentyeva | ||
| "... to December 2015. The data of state statistical supervision, registered limit transfer drug prices from ..." | ||
| Vol 10, No 2 (2017) | COST-MINIMIZATION OF VILANTEROL / UMECLIDINIUM VERSUS OLODATEROL / TIOTROPIUM IN THE BASIC THERAPY OF SEVERE AND VERY SEVERE COPD | Abstract similar documents |
| E. G. Kosolapov, F. S. Kochenkov, N. L. Pogudina, D. V. Blinov, N. L. Bondarenko, A. V. Karaulov | ||
| "... , and instructions for medical use to conduct a cost analysis that was based on the prices for these medications ..." | ||
| Vol 10, No 2 (2017) | PHARMACOECONOMIC ASPECTS OF NON-SMALL CELL LUNG CANCER IMMUNOTHERAPY | Abstract similar documents |
| A. V. Rudakova, S. A. Protsenko, I. A. Koroleva | ||
| "... of treatment (in the basic version) is 5.7% lower than that for nivolumab. When prices vary within reasonable ..." | ||
| Vol 11, No 3 (2018) | Determination of a willingness-to-pay threshold and decision-making in financing the healthcare technologies | Abstract similar documents |
| T. S. Teptsova, T. P. Bezdenezhnyh, V. K. Fedyaeva, N. Z Musina, G. R. Hachatryan, V. V. Tarasov | ||
| "... was calculated based on the shadow budget price (i. e. determining the WTPT by the suppling party). This method ..." | ||
| Vol 16, No 3 (2023) | Updated pharmacoeconomic analysis of atesolizumab efficiency compared with other PD-1 inhibitors in patients with advanced non-small cell lung cancer after chemotherapy | Abstract similar documents |
| S. K. Zyryanov, I. N. Dyakov | ||
| "... . For calculations, we used registered prices according to the state register of maximum selling prices and average ..." | ||
| Vol 17, No 4 (2024) | Pharmacoeconomic analysis of netakimab in the treatment of ankylosing spondylitis: perspective of Russian healthcare system | Abstract similar documents |
| A. V. Rudakova, I. Z. Gaydukova | ||
| "... to the registered maximum retail prices, inclusive of value-added tax. In case of availability of biosimilars ..." | ||
| Vol 7, No 4 (2014) | IS RUSSIA READY FOR THE INTRODUCTION OF THE NATIONAL REFERENCE PRICING SYSTEM? | Abstract similar documents |
| V. V. Omelyanovskiy | ||
| "... , internal and external price regulation can be distinguished. External referencing system has been used ..." | ||
| 1 - 50 of 111 Items | 1 2 3 > >> | |
Search tips:
- Search terms are case-insensitive
- Common words are ignored
- By default articles containing any term in the query are returned (i.e., OR is implied)
- Make sure that a word exists in an article by prefixing it with +; e.g., +journal +access scholarly academic
- Combine multiple words with AND to find articles containing all terms; e.g., education AND research
- Exclude a word by prefixing it with - or NOT; e.g., online -politics or online NOT politics
- Search for an exact phrase by putting it in quotes; e.g., "open access publishing". Hint: Quoting Chinese or Japanese words will help you to find exact word matches in mixed-language fields, e.g. "中国".
- Use parentheses to create more complex queries; e.g., archive ((journal AND conference) NOT theses)
